151 related articles for article (PubMed ID: 35358351)
1. Mismatch repair deficiency and clinical implications in prostate cancer.
Graham LS; Schweizer MT
Prostate; 2022 Aug; 82 Suppl 1():S37-S44. PubMed ID: 35358351
[TBL] [Abstract][Full Text] [Related]
2. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract][Full Text] [Related]
3. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.
Atwal A; Snowsill T; Dandy MC; Krum T; Newton C; Evans DG; Crosbie EJ; Ryan NAJ
Int J Cancer; 2022 Nov; 151(9):1626-1639. PubMed ID: 35792468
[TBL] [Abstract][Full Text] [Related]
5. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
[TBL] [Abstract][Full Text] [Related]
6. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
7. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
8. Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD; Michaels T; Bellone S; Hartwich TMP; Bonazzoli E; Iwasaki A; Song E; Santin AD
Cancer Discov; 2023 Feb; 13(2):312-331. PubMed ID: 36301137
[TBL] [Abstract][Full Text] [Related]
9. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
Reed-Perino DE; Lai M; Yu EY; Schweizer MT
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
[TBL] [Abstract][Full Text] [Related]
10. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity.
Westcott PMK; Muyas F; Hauck H; Smith OC; Sacks NJ; Ely ZA; Jaeger AM; Rideout WM; Zhang D; Bhutkar A; Beytagh MC; Canner DA; Jaramillo GC; Bronson RT; Naranjo S; Jin A; Patten JJ; Cruz AM; Shanahan SL; Cortes-Ciriano I; Jacks T
Nat Genet; 2023 Oct; 55(10):1686-1695. PubMed ID: 37709863
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
13. Mismatch repair deficiency: The what, how and why it is important.
Olave MC; Graham RP
Genes Chromosomes Cancer; 2022 Jun; 61(6):314-321. PubMed ID: 34837268
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and mismatch repair deficiency in the era of precision immuno-oncology.
Mann SA; Cheng L
Expert Rev Anticancer Ther; 2020 Jan; 20(1):1-4. PubMed ID: 31842633
[No Abstract] [Full Text] [Related]
15. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
16. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
17. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
18. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas - institutional experience and review of literature.
Alphones S; Chatterjee U; Singh A; Das A; Zameer L; Achari R; Bhattacharya A; Roy P
Childs Nerv Syst; 2021 Aug; 37(8):2521-2530. PubMed ID: 34097097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
